Wednesday, August 15, 2018—The US Food and Drug Administration (FDA) has approved patisiran (Onpattro; Alnylam Pharmaceuticals, Cambridge, MA) for treatment of polyneuropathy in adults with hereditary t…
Monday, July 30, 2018—In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safel…
Thursday, July 26, 2018—Antisense oligonucleotide (ASO) therapy is a new class of treatment of people with illnesses caused by defects in a single gene. In this novel approach, instead of repairing o…
Friday, July 13, 2018—The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatmen…
Tuesday, June 26, 2018—BrainStorm Cell Therapeutics Inc. has announced that after careful consideration of the newly enacted right-to-try (RTT) legislation, it will not make stem-cell therapy (Nurow…
Friday, June 01, 2018—Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regar…
Thursday, April 26, 2018—At the American Academy of Neurology (AAN), researchers Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, and Rozalina Dimitrova presented results evaluating the …
Wednesday, April 04, 2018—The first patients to complete the phase 2 clinical trial of AMX0035 (Amylyx; Cambridge, MA), a combination of phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), for a…
